NeuroSky company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 2 yrs ago

About NeuroSky

NeuroSky is at the forefront of body and mind monitoring and analysis. Its technologies are at the core of innovative, wearable health and wellness consumer products. NeuroSky makes it possible for millions of consumers to capture and quantify critical health and wellness data so that they can effectively manage their mind and body health. NeuroSky delivers uniquely adaptable chips and algorithms that offer ECG multi-function cardio monitoring, and quantitive and interpretive algorithms in a powerful integrated, adaptable and extensible solution.

NeuroSky Headquarters Location

125 South Market Street

San Jose, California, 95113,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NeuroSky

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuroSky is included in 6 Expert Collections, including Wearable Computing.


Wearable Computing

408 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.


Fitness Tech

1,431 items

This Collection includes startups developing software and technology to augment approaches to developing or maintaining physical fitness, including workout apps, wearables, and connected fitness equipment.


Medical Devices

8,452 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Smart Home & Consumer Electronics

1,167 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.


Health Monitoring & Diagnostics

462 items

Companies developing wearable health monitoring solutions (human health only). Companies tagged as #Wearables (*note: this tag may also apply to companies outside the scope of this collection)


Health IT

7,900 items

NeuroSky Patents

NeuroSky has filed 21 patents.

patents chart

Application Date

Grant Date


Related Topics




Sensors, Biosensors, Biotechnology, Gas sensors, Transducers


Application Date


Grant Date



Related Topics

Sensors, Biosensors, Biotechnology, Gas sensors, Transducers



Latest NeuroSky News

Starfleet Innotech leadership mobilizes across North America with strategic meetings in US, Canada

May 12, 2022

Hamilton, NEW ZEALAND NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Starfleet Innotech , Inc. (OTC Pink: SFIO) (" SFIO " or “The "Company") caps off the first leg of its US roadshow with a successful showing at the Planet MicroCap conference in Las Vegas, strategic meetings with Silicon Valley partners in Palo Alto. Towards the end of the month, executives from the global conglomerate will be congregating in New York to cement the agreements necessary to establish a more concrete presence in the United States. “While we already have a presence in the United States through our office, key personnel, and strategic partners, our showcase in Las Vegas formally kicks off the next phase of our growth as a conglomerate,” said Santiago Arnaiz, General Manager of Communications at SFIO. “We recognize the crucial role that North America plays as fertile grounds to stage our global expansion. There are incredibly exciting projects being launched across the SFIO ecosystem—in the Philippines, Dubai, Malaysia, and beyond—all vital parts of our growth journey. Our job here in the US is to find partners interested in joining us on that journey. The reception so far has been promising.” As a global investment holding company, SFIO is focused on innovation through disruptive collaborations across its three key industries: Food and Beverage (F&B), Real Estate, and Technology. This translates to making strategic investments in high-growth businesses and building synergies across its diverse portfolio in order to provide maximum shareholder value. SFIO currently maintains offices across New Zealand, Australia, Malaysia, the United Arab Emirates, the Philippines, and the United States. Over the next few months, the SFIO team will be mobilizing across North America , building on its momentum in Las Vegas and San Francisco, towards establishing a more concrete presence in the region. Last week, both Arnaiz and Chief Investor Officer Richard De Lima presented SFIO at the Planet MicroCap showcase to an audience of investors, fund managers, and family offices. In Toronto, CEO Jeths Lacson has mobilized a signed partnership with the company’s Canadian distributor for Gorgeous Coffee and Epiphany Manuka Honey products . Under this agreement, the company’s F&B products will be made available for purchase online through Amazon, and eventually through major retail outlets across North America. Meanwhile, Chief Technology Officer Richard Prodigalidad met with technology partners in San Francisco and Palo Alto, including biotech wearable developer NeuroSky . Wearables developed by NeuroSky are set to be integrated into SFIO’s real estate projects under the Moraya brand of wellness-oriented, tech-enabled townships. Deployed through Project Fort, a community health dashboard service and subsidiary of SFIO, these wearables will gather the data necessary to pioneer entirely new approaches to proactive community care . In addition to ecosystem partners, Prodigalidad secured commitments to connect the increasing demand for tech talent across Silicon Valley with highly-skilled developers and designers based in the Philippines—positioning SFIO as the central hub in a global innovation ecosystem. More details on this new initiative will be shared in the months to come. “The work continues in connecting with investors and other growth enablers to take SFIO to the next level. We have a full lineup of meetings over the next few weeks, ranging from exploratory chats, follow-up sessions stemming from our recent participation at Planet MicroCap, and deep-dives into partnership agreements,” said Arnaiz. “It was exciting to get to sit down with our partners in Silicon Valley to kick off our co-creation efforts in technology. I’m looking forward to doing the same in New York, representing our businesses like Epiphany Cafe with potential F&B partners.” Among these potential partners are major distributors, retail stores, manufacturers, and cafe franchises—with whom SFIO hopes to bring its F&B businesses like Epiphany Cafe and Gorgeous Coffee into the country. To support these growth efforts, the company will be engaging with a US-focused IR firm to bolster its traction in this crucial market. “Our goal at SFIO is to bridge promising businesses from emerging economies with crucial growth enablers, many of which are based in the United States,” said Arnaiz. “Over the last year or so, we’ve been hard at work championing those promising businesses. Now we’re shifting our focus to the US, to build the other side of that global infrastructure. While here, we’ll be looking to accomplish three things: strike strategic partnerships with institutional players, increase visibility on our global businesses, and gather the resources we need to get Starfleet soaring.” For media enquiries, please contact: Craymond Yeong, PR & Marketing Specialist Starfleet Innotech, Inc.

NeuroSky Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NeuroSky Rank

  • When was NeuroSky founded?

    NeuroSky was founded in 2004.

  • Where is NeuroSky's headquarters?

    NeuroSky's headquarters is located at 125 South Market Street, San Jose.

  • What is NeuroSky's latest funding round?

    NeuroSky's latest funding round is Loan.

  • How much did NeuroSky raise?

    NeuroSky raised a total of $12.05M.

  • Who are the investors of NeuroSky?

    Investors of NeuroSky include Paycheck Protection Program, SoftBank Group, Taiwan Global BioFund, WR Hambrecht + Co., Taicom Capital and 4 more.

  • Who are NeuroSky's competitors?

    Competitors of NeuroSky include Muse, NextMind, eSight, Bioness, Freer Logic and 15 more.

You May Also Like


Truthtek is a spin-out company from Manchester Metropolitan University with a suite of software for the analysis of non-verbal behaviour in video streams of structured interviews. The technology combines latest psychological research in non-verbal communication with leading image recognition and analysis software. Potential applications include lie detection, where the technology is non-invasive and has shown 85% accuracy in initial trials. MTF has provided initial seed capital to the company to enable it to develop its commercial and market-entry strategy.


DIRAmed is developing non-invasive meters that measure the levels of key constituents of the human body such as glucose, ketones, cholesterol, and therapeutic drugs. DIRAmed's meters will improve the process by which diabetics and other patients taking therapeutic drugs monitor the levels of components in blood and tissue. DIRAmed currently has investigational prototypes in clinical studies for use in improving tight glycemic control in hospital critical care continuous glucose monitoring applications. DIRAmed is also discussing other designs with selected strategic partners including the development of mobile units for personal use with or without connection to an insulin pump.


DermIng, an independent private research Institute, carries out a series of clinical trials to measure the activity and tolerance of skin care treatments and products, and also developers the very latest non-invasive diagnostic bio-engineering systems.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

River Diagnostics

River Diagnostics is dedicated to the development of products for the healthcare and medical research marketplace based on the vast potential of non-invasive/non-destructive Raman spectroscopy. Today researchers in personal care, and dermatological research are using River Diagnostics' instruments to understand the metabolic processes in the skin, and other fundamental research questions.


Biopeaks vision is to develop leading edge non-invasive blood analysis devices.  The company's early research focused on lactic acid analysis for the performance athletic market.  As technical results and market information, the company contends that Biopeaks technology was ideal for other larger markets including glucose monitoring. Biopeak is now actively developing a noninvasive glucose analyzer based on its Fusion Spectroscopy technology platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.